KREBSBIO vs LASA: Stock Comparison
KREBS BIOCHEMICALS & IND is the larger company by market capitalisation. KREBS BIOCHEMICALS & IND shows faster revenue growth, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
KREBSBIO leads 5; LASA leads 2 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | KREBSBIO | LASA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | KREBSBIO | LASA |
|---|---|---|
| Live Price | ₹55.95 | ₹6.73 |
| Day Change | 2.66% | -1.32% |
| Volume | 5,830 | 24,575 |
| 52-Week High | ₹82.49 | ₹14.08 |
| 52-Week Low | ₹38.33 | ₹5.67 |
| Distance from 52W High | -32.17% | -52.2% |
Valuation
| Metric | KREBSBIO | LASA |
|---|---|---|
| Market Cap | ₹121 Cr | ₹34 Cr |
| P/E Ratio | 0x | — |
| P/B Ratio | 0x | — |
| EPS | ₹-1.15 | ₹-0.71 |
| Book Value | — | ₹9.9 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | KREBSBIO | LASA |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.6% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -70.57% | -95.12% |
| Qtr Profit Growth | 85.33% | 89.5% |
Profitability & Leverage
| Metric | KREBSBIO | LASA |
|---|---|---|
| ROE | — | -68.7% |
| ROCE | -15.89% | -57.92% |
| Net Margin | -71.35% | -135.6% |
| Operating Margin | -41.49% | -136.12% |
| Debt to Equity | — | 0.2x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | KREBSBIO | LASA |
|---|---|---|
| Promoter Holding | 72.74% | 53.65% |
| FII Holding | 0.5% | 0% |
| DII Holding | 0% | 0% |
| Public Holding | 26.76% | 46.35% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KREBS BIOCHEMICALS & IND and LASA SUPERGENERICS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.